Lilly.Com

board

Company

select Filter
All
Business
Culture
Environment
Health
Politics
Research

Key facts

Latest news (see all)

Eli Lilly's Zepbound in shortage months after approval

Read: The Hill

2024-04-18

Sleep Apnea Reduced in People Who Took Zepbound, Eli Lilly Reports

Read: The New York Times

2024-04-18

As Zepbound shortage grows, Eli Lilly says there's no immediate end in sight

Read: NBC News

2024-04-18

Eli Lilly weight loss injection drug also helps with obstructive sleep apnea, company says

Read: The Washington Times

2024-04-17

Promise of Eli Lilly's weight-loss drug for sleep apnea adds another reason to own the stock

Read: CNBC News

2024-04-17

Eli Lilly's weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials

Read: CNBC News

2024-04-17

Even more doses of Eli Lilly's Zepbound and Mounjaro are officially in a shortage, FDA says

Read: Quartz

2024-04-17

Metrics

Business

assets 48.8B $
Debt 16.6B $
free cash flow 4,736,290,000.00
market cap 299,054,000,000.00
profits 5.6B $

Visualizations

Datasets

Source

Twitter, YAHOO-FIN, YFINANCE

Updated: 4 days ago

License

CC BY 4.0

dark About